IP waiver won’t solve vaccine problems, warn experts

A landmark proposal to suspend provisions of TRIPS for COVID-19 vaccines and treatments was first raised in October 2020. But, nearly a year and a half later, in January 2022, it seems there is no end in sight, with members of the World Trade Organization (WTO) failing to reach consensus.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

AstraZeneca partners with Chinese firm ahead of next obesity race

5 February 2026 The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.

Europe

INTA: ‘Davos of IP’ will take London meeting to a ‘different level’

5 February 2026 Excitement is mounting for the world’s largest IP gathering, which will see the industry’s elites travelling to the UK in the spring, reveals the association’s CEO.

Careers

Nine-partner litigation team leaves Winston & Strawn

5 February 2026 The trial group, which brings “exceptional litigation talent”, joins larger firm in Texas and Washington, DC, coinciding with the announcement of the Winston Taylor merger.

More features

AstraZeneca partners with Chinese firm ahead of next obesity race

INTA: ‘Davos of IP’ will take London meeting to a ‘different level’

Nine-partner litigation team leaves Winston & Strawn

Squire Patton Boggs brings in tech and data expert as Ireland practice lead

LSPN Awards USA returns for second year—with new categories

Drowning in EU regulations? Five tips for surviving the deluge of new rules

Moderna VP and regulatory expert moves to private practice

Crowell adds tech partner with in-house and private practice expertise

IP waiver won’t solve vaccine problems, warn experts

More on this story

Editor's picks

Editor's picks

More features